SEC Form 4 · accession 0001179110-19-003597
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James DArecca
Officer — SVP Chief Accounting Officer
Period of report
Mar 6, 2019
Accepted (ET)
Mar 8, 2019 · 3:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1,F2 | Mar 6, 2019 | A | 2,036 | $137.51 | A | 7,505 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 6, 2020, twenty-five percent (25%) on March 6, 2021, twenty-five percent (25%) on March 6, 2022 and twenty-five percent (25%) on March 6, 2023.
- F2Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.